Drug Trial Radar · NCT06854445
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Mar 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
55
Planned (sponsor's estimate)
Start
Mar 12, 2025
Primary completion
Oct 2025
Study completion Feb 2028
Sponsor
- Lead sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the preliminary efficacy of TQB2825 in combination with chemotherapy in subjects with diffuse large B-cell lymphoma.
Conditions
- Diffuse Large Cell B-lymphoma
Interventions
TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for InjectionDrug
Drug: TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection; Other Name: Gemcitabine Hydrochloride for Injection, Zefei; Oxaliplatin for Injection, Aihen TQB2825 injection is Cluster of Differentiation 3 (CD3) and and Cluster of Differentiation 20 (CD20) bispecific antibody; Gemcitabine hydrochloride for injection is a cell cycle-specific antimetabolite; Oxaliplatin for Injection is a platinum chemotherapy drug.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete response rate (CR rate)Time frame: 1 year
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Wannan Medical College
Wuhu, Anhui, China · Not yet recruiting
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China · Not yet recruiting
Gansu Provincial Cancer Hospital
Lanzhou, Gansu, China · Not yet recruiting
Affiliated Cancer Hospital and insititute Guangzhou Medical University
Guangzhou, Guangdong, China · Not yet recruiting
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China · Not yet recruiting
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Not yet recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Not yet recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Not yet recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Not yet recruiting
Hubei Cancer Hospital (HBCH)
Wuhan, Hubei, China · Not yet recruiting
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China · Not yet recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Not yet recruiting
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China · Not yet recruiting
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China · Not yet recruiting
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Not yet recruiting
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China · Not yet recruiting
The Second Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China · Recruiting
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China · Not yet recruiting
Shandong cancer hospital
Jinan, Shandong, China · Not yet recruiting
Weihai Central Hospital
Weihai, Shandong, China · Not yet recruiting
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, China · Not yet recruiting
Sichuan Provincal People's Hospital
Chengdu, Sichuan, China · Not yet recruiting
The Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, China · Not yet recruiting
THE First Affiliated Hospital ZheJiang University School of Medicine
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.